Suppr超能文献

miR-20a 在乳腺癌中的血管生成作用。

Angiogenic role of miR-20a in breast cancer.

机构信息

Department of Hematology and Medical Oncology, Hospital Universitario Morales Meseguer y Centro Regional de Hemodonación, Murcia, Spain.

Department of Internal Medicine, University of Murcia, Murcia, Spain.

出版信息

PLoS One. 2018 Apr 4;13(4):e0194638. doi: 10.1371/journal.pone.0194638. eCollection 2018.

Abstract

BACKGROUND

Angiogenesis is a key process for tumor progression and a target for treatment. However, the regulation of breast cancer angiogenesis and its relevance for clinical resistance to antiangiogenic drugs is still incompletely understood. Recent developments on the contribution of microRNA to tumor angiogenesis and on the oncogenic effects of miR-17-92, a miRNA cluster, point to their potential role on breast cancer angiogenesis. The aim of this work was to establish the contribution of miR-20a, a member of miR-17-92 cluster, to tumor angiogenesis in patients with invasive breast carcinoma.

METHODS

Tube-formation in vitro assays with conditioned medium from MCF7 and MDA-MB-231 breast cancer cell lines were performed after transfection with miR-20a and anti-miR20a. For clinical validation of the experimental findings, we performed a retrospective analysis of a series of consecutive breast cancer patients (n = 108) treated with neoadjuvant chemotherapy and with a full characterization of their vessel pattern and expression of angiogenic markers in pre-treatment biopsies. Expression of members of the cluster miR-17-92 and of angiogenic markers was determined by RT-qPCR after RNA purification from FFPE samples.

RESULTS

In vitro angiogenesis assays with endothelial cells and conditioned media from breast cancer cell lines showed that transfection with anti-miR20a in MDA-MB-231 significantly decreased mean mesh size and total mesh area, while transfection with miR-20a in MCF7 cells increased mean mesh size. MiR-20a angiogenic effects were abrogated by treatment with aflibercept, a VEGF trap. These results were supported by clinical data showing that mir-20a expression was higher in tumors with no estrogen receptor or with more extensive nodal involvement (cN2-3). A higher miR-20a expression was associated with higher mean vessel size (p = 0.015) and with an angiogenic pattern consisting in larger vessels, higher VEGFA expression and presence of glomeruloid microvascular proliferations (p<0.001). This association was independent of tumor subtype and VEGFA expression.

CONCLUSIONS

Transfection of breast cancer cells with miR-20a induces vascular changes in endothelial tube-formation assays. Expression of miR-20a in breast invasive carcinomas is associated with a distinctive angiogenic pattern consisting in large vessels, anomalous glomeruloid microvascular proliferations and high VEGFA expression. Our results suggest a role for miR-20a in the regulation of breast cancer angiogenesis, and raise the possibility of its use as an angiogenic biomarker.

摘要

背景

血管生成是肿瘤进展的关键过程,也是治疗的靶点。然而,乳腺癌血管生成的调节及其与抗血管生成药物临床耐药性的关系仍不完全清楚。最近关于 microRNA 对肿瘤血管生成的贡献以及 miR-17-92 微 RNA 簇的致癌作用的研究进展表明,它们可能在乳腺癌血管生成中发挥作用。本研究的目的是确定 miR-20a(miR-17-92 簇的一个成员)在浸润性乳腺癌患者肿瘤血管生成中的作用。

方法

用 MCF7 和 MDA-MB-231 乳腺癌细胞系的条件培养基进行体外管形成实验,转染 miR-20a 和抗 miR20a。为了验证实验结果的临床意义,我们对一系列连续的接受新辅助化疗的乳腺癌患者(n=108)进行了回顾性分析,并对其治疗前活检中的血管模式和血管生成标志物的表达进行了全面描述。从 FFPE 样本中提取 RNA 后,通过 RT-qPCR 确定 miR-17-92 簇成员和血管生成标志物的表达。

结果

用内皮细胞和乳腺癌细胞系的条件培养基进行的体外血管生成实验表明,MDA-MB-231 中转染抗 miR-20a 显著降低了平均网格大小和总网格面积,而 MCF7 细胞中转染 miR-20a 则增加了平均网格大小。用 VEGF 陷阱 aflibercept 处理可阻断 miR-20a 的血管生成作用。这些结果得到了临床数据的支持,这些数据表明,在没有雌激素受体或淋巴结受累更广泛的肿瘤中(cN2-3),mir-20a 的表达更高。较高的 miR-20a 表达与较高的平均血管大小(p=0.015)和较大的血管、较高的 VEGFA 表达以及存在肾小球样微血管增殖(p<0.001)有关。这种关联与肿瘤亚型和 VEGFA 表达无关。

结论

转染乳腺癌细胞的 miR-20a 可诱导内皮细胞管状形成实验中的血管变化。乳腺浸润性癌中 miR-20a 的表达与一种独特的血管生成模式有关,该模式包括大血管、异常的肾小球样微血管增殖和高 VEGFA 表达。我们的结果表明 miR-20a 在调节乳腺癌血管生成中发挥作用,并提出了将其用作血管生成生物标志物的可能性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a24d/5884522/3e2c91123125/pone.0194638.g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验